Immunotherapy comprising TLR9 ligand and CD40 ligand
US9161976B2 · kind B2 · utility
12Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 22, 2012 |
| Grant date | Oct 20, 2015 |
| Priority date | — |
| Expiry date | Feb 3, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.